Trumenba (meningococcal group b vaccine (recombinant, adsorbed))
- Region
- 🇪🇺 EU
- Active substance
- meningococcal group b vaccine (recombinant, adsorbed)
- Company
- Pfizer Europe MA EEIG
- Status
- Authorised
- Therapeutic area
- Meningitis, Meningococcal
- CHMP opinion
- Thu 23 Feb 2017
- EU approval
- Wed 24 May 2017
- Application
- EMEA/H/C/004051
- ATC
- J07AH09
- Official record
- www.ema.europa.eu
Indication
Trumenba is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B. The use of this vaccine should be in accordance with official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Follow Trumenba
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.